ALK and non-small cell lung carcinoma: We used a decision model to estimate the costs, QALYs, and incremental cost-effectiveness ratios of two commonly used ALK rearrangement screening tests, NGS panel tests and multiplex PCR testing, which are used to guide treatment decisions about crizotinib treatment in advanced NSCLC.